{"filing":{"accession_number":"0001171843-26-004399","cik":"0001643918","ticker":"BDRX","company_name":"Biodexa Pharmaceuticals Plc","form":"6-K","filing_date":"2026-06-30","report_date":null,"primary_document":"f6k_063026.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1643918/000117184326004399/f6k_063026.htm"},"events":[{"id":15020,"run_id":13400,"accession_number":"0001171843-26-004399","anchor_item_number":"EX-99.1","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"This press release announces the results of Biodexa's Annual General Meeting held on June 30, 2026, disclosing voting outcomes for 11 resolutions: ordinary resolutions 1–7 passed with majorities ranging from 73% to 94%, while ordinary resolution 8 and special resolution 10 failed to pass, with resolution 11 also failing as it was contingent on resolution 8. This is a direct disclosure of shareholder vote results at an annual meeting, matching the shareholder_vote_results event type.","company_name":"Biodexa Pharmaceuticals Plc","ticker":"BDRX","filing_date":"2026-06-30","form":"6-K","submitted_at":null,"items":[{"id":12629,"accession_number":"0001171843-26-004399","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This press release announces the results of Biodexa's Annual General Meeting held on June 30, 2026, disclosing voting outcomes for 11 resolutions: ordinary resolutions 1–7 passed with majorities ranging from 73% to 94%, while ordinary resolution 8 and special resolution 10 failed to pass, with resolution 11 also failing as it was contingent on resolution 8. This is a direct disclosure of shareholder vote results at an annual meeting, matching the shareholder_vote_results event type.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-01T02:19:44.783829+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":12629,"accession_number":"0001171843-26-004399","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This press release announces the results of Biodexa's Annual General Meeting held on June 30, 2026, disclosing voting outcomes for 11 resolutions: ordinary resolutions 1–7 passed with majorities ranging from 73% to 94%, while ordinary resolution 8 and special resolution 10 failed to pass, with resolution 11 also failing as it was contingent on resolution 8. This is a direct disclosure of shareholder vote results at an annual meeting, matching the shareholder_vote_results event type.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-01T02:19:44.783829+00:00","company_name":"Biodexa Pharmaceuticals Plc","ticker":"BDRX","filing_date":"2026-06-30"}]}